Klebsiella pneumoniae Infections – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Klebsiella pneumoniae Infections – Pipeline Review, H1 2018’, provides an overview of the Klebsiella pneumoniae Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections

– The report reviews pipeline therapeutics for Klebsiella pneumoniae Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Klebsiella pneumoniae Infections therapeutics and enlists all their major and minor projects

– The report assesses Klebsiella pneumoniae Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Klebsiella pneumoniae Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

ABAC Therapeutics SA

Acies Bio doo

AmpliPhi Biosciences Corp

Appili Therapeutics Inc

C3J Therapeutics Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

Debiopharm International SA

Evaxion Biotech ApS

F. Hoffmann-La Roche Ltd

Innovation Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

LegoChem Biosciences Inc

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Nosopharm SAS

Peptilogics Inc

Pfizer Inc

Phico Therapeutics Ltd

Sarepta Therapeutics Inc

Shionogi & Co Ltd

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Vaxdyn SL

Venus Medicine Research Center

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 7

Global Markets Direct Report Coverage 7

Klebsiella pneumoniae Infections Overview 8

Klebsiella pneumoniae Infections Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 13

Products under Development by Companies 14

Products under Development by Universities/Institutes 17

Klebsiella pneumoniae Infections Therapeutics Assessment 18

Assessment by Target 18

Assessment by Mechanism of Action 20

Assessment by Route of Administration 22

Assessment by Molecule Type 24

Klebsiella pneumoniae Infections Companies Involved in Therapeutics Development 26

ABAC Therapeutics SA 26

Acies Bio doo 26

AmpliPhi Biosciences Corp 26

Appili Therapeutics Inc 27

C3J Therapeutics Inc 27

ContraFect Corp 28

Daiichi Sankyo Co Ltd 28

Debiopharm International SA 28

Evaxion Biotech ApS 29

F. Hoffmann-La Roche Ltd 29

Innovation Pharmaceuticals Inc 30

Kyorin Pharmaceutical Co Ltd 30

LegoChem Biosciences Inc 31

Meiji Seika Pharma Co Ltd 31

Melinta Therapeutics Inc 31

Nosopharm SAS 32

Peptilogics Inc 32

Pfizer Inc 33

Phico Therapeutics Ltd 33

Sarepta Therapeutics Inc 34

Shionogi & Co Ltd 34

Syntiron LLC 35

Tetraphase Pharmaceuticals Inc 35

Vaxdyn SL 36

Venus Medicine Research Center 36

Klebsiella pneumoniae Infections Drug Profiles 37

Antibodies for Klebsiella pneumoniae Infections Drug Profile 37

Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections Drug Profile 38

ASN-300 Drug Profile 39

ATI-1503 Drug Profile 40

Biologics for Bacterial Infections Drug Profile 41

C-3JEPXX Drug Profile 42

CA-824 Drug Profile 43

CC-1807 Drug Profile 44

cefiderocol sulfate tosylate Drug Profile 45

Debio-1454 Drug Profile 50

DS-86760016 Drug Profile 51

EBX-004 Drug Profile 52

EVXB-2 Drug Profile 53

FG-LpxC Drug Profile 54

FPI-1465 Drug Profile 56

GN Snare Drug Profile 58

GYR-12 Drug Profile 59

IBN-1 Drug Profile 60

kelokardin Drug Profile 61

Klebsiella pneumonia vaccine Drug Profile 62

Klebsiella pneumoniae vaccine Drug Profile 63

Klebsiella pneumoniae vaccine Drug Profile 64

LCB-180055 Drug Profile 65

Monoclonal Antibodies to Inhibit Carbapenemase for Klebsiella pneumoniae and Acinetobacter baumannii Infections Drug Profile 66

NCL-195 Drug Profile 67

NOSO-502 Drug Profile 68

NOSO-95179 Drug Profile 69

Onc-72 Drug Profile 70

OTP-602 Drug Profile 71

Peptides for Infectious Diseases Drug Profile 72

PT-4 Drug Profile 73

Recombinant Enzyme to Disrupt Bacterial Cell Wall for Gram Negative Bacterial Infections Drug Profile 74

RX-04 Drug Profile 75

RXP-873 Drug Profile 78

Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections Drug Profile 80

Small Molecules for Bacterial and Fungal Infections Drug Profile 81

Small Molecules for Bacterial Infections Drug Profile 82

Small Molecules for Bacterial Infections Drug Profile 83

Small Molecules for Klebsiella pneumoniae Infections Drug Profile 84

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections Drug Profile 85

Small Molecules to Inhibit KasA for Gram-Positive and Gram-Negative Bacterial Infections Drug Profile 86

Small Molecules to Inhibit Lipopolysaccharide for Bacterial and Nosocomial Infections Drug Profile 87

SPR-741 Drug Profile 88

tebipenem pivoxil Drug Profile 91

TP-6076 Drug Profile 92

VRP-001 Drug Profile 94

VXD-004 Drug Profile 95

WLBU-2 Drug Profile 96

Klebsiella pneumoniae Infections Dormant Projects 97

Klebsiella pneumoniae Infections Discontinued Products 99

Klebsiella pneumoniae Infections Product Development Milestones 100

Featured News & Press Releases 100

Appendix 106

Methodology 106

Coverage 106

Secondary Research 106

Primary Research 106

Expert Panel Validation 106

Contact Us 106

Disclaimer 107

List of Tables

List of Tables

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Klebsiella pneumoniae Infections Pipeline by ABAC Therapeutics SA, H1 2018

Klebsiella pneumoniae Infections Pipeline by Acies Bio doo, H1 2018

Klebsiella pneumoniae Infections Pipeline by AmpliPhi Biosciences Corp, H1 2018

Klebsiella pneumoniae Infections Pipeline by Appili Therapeutics Inc, H1 2018

Klebsiella pneumoniae Infections Pipeline by C3J Therapeutics Inc, H1 2018

Klebsiella pneumoniae Infections Pipeline by ContraFect Corp, H1 2018

Klebsiella pneumoniae Infections Pipeline by Daiichi Sankyo Co Ltd, H1 2018

Klebsiella pneumoniae Infections Pipeline by Debiopharm International SA, H1 2018

Klebsiella pneumoniae Infections Pipeline by Evaxion Biotech ApS, H1 2018

Klebsiella pneumoniae Infections Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Klebsiella pneumoniae Infections Pipeline by Innovation Pharmaceuticals Inc, H1 2018

Klebsiella pneumoniae Infections Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2018

Klebsiella pneumoniae Infections Pipeline by LegoChem Biosciences Inc, H1 2018

Klebsiella pneumoniae Infections Pipeline by Meiji Seika Pharma Co Ltd, H1 2018

Klebsiella pneumoniae Infections Pipeline by Melinta Therapeutics Inc, H1 2018

Klebsiella pneumoniae Infections Pipeline by Nosopharm SAS, H1 2018

Klebsiella pneumoniae Infections Pipeline by Peptilogics Inc, H1 2018

Klebsiella pneumoniae Infections Pipeline by Pfizer Inc, H1 2018

Klebsiella pneumoniae Infections Pipeline by Phico Therapeutics Ltd, H1 2018

Klebsiella pneumoniae Infections Pipeline by Sarepta Therapeutics Inc, H1 2018

Klebsiella pneumoniae Infections Pipeline by Shionogi & Co Ltd, H1 2018

Klebsiella pneumoniae Infections Pipeline by Syntiron LLC, H1 2018

Klebsiella pneumoniae Infections Pipeline by Tetraphase Pharmaceuticals Inc, H1 2018

Klebsiella pneumoniae Infections Pipeline by Vaxdyn SL, H1 2018

Klebsiella pneumoniae Infections Pipeline by Venus Medicine Research Center, H1 2018

Klebsiella pneumoniae Infections Dormant Projects, H1 2018

Klebsiella pneumoniae Infections Dormant Projects, H1 2018 (Contd..1), H1 2018

Klebsiella pneumoniae Infections Discontinued Products, H1 2018

List of Figures

List of Figures

Number of Products under Development for Klebsiella pneumoniae Infections, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports